Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial. - Wikidata - wikimedia - TriplyDB

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

http://www.wikidata.org/entity/Q34664004

about

Insights on GRACE (Gender, Race, And Clinical Experience) from the patient's perspective: GRACE participant survey Barriers to a cure for HIV in women Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK Studies.Effectiveness of first-line antiretroviral therapy in the IPEC cohort, Rio de Janeiro, Brazil.Impact of gender on response to highly active antiretroviral therapy in HIV-1 infected patients: a nationwide population-based cohort study.Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study Immigrant women living with HIV in Spain: a qualitative approach to encourage medical follow-up Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.Sex, age, race and intervention type in clinical studies of HIV cure: a systematic review.Health needs of HIV-infected women in the United States: insights from the women living positive survey.Recruitment and retention of diverse populations in antiretroviral clinical trials: practical applications from the gender, race and clinical experience study.Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment.Effects of darunavir/ritonavir-based therapy on metabolic and anthropometric parameters in women and men over 48 weeks.Health-related quality of life in the gender, race, and clinical experience trial.Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1-Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial.Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.How do outcomes compare between women and men living with HIV in Australia? An observational study.Prevalence of Drug Resistance and Associated Mutations in a Population of HIV-1(+) Puerto Ricans: 2006-2010.Women in HIV cure research: multilevel interventions to improve sex equity in recruitment.Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial Caring for women living with HIV: gaps in the evidence.Issues in women's participation in a phase III community HIV vaccine trial in Thailand Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV.Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy.Effect of darunavir on lipid profile in HIV-infected patients.Differences in implementation of HIV/AIDS clinical research in developed versus developing world: an evidence-based review on protease inhibitor use among women and minorities.Darunavir: a review of its use in the management of HIV-1 infection.Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.Response to combined antiretroviral therapy according to gender and origin in a cohort of naïve HIV-infected patients: GESIDA-5808 study.Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).Are there differences in disease progression and mortality among male and female HIV patients on antiretroviral therapy? A meta-analysis of observational cohorts.The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy.Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE.Impact of baseline virologic, immunologic, and demographic characteristics on virologic responses in the Gemini study.Sex Differences in HIV Infection.Sex-based differences in antiretroviral therapy initiation, switching and treatment interruptions: global overview from the International Epidemiologic Databases to Evaluate AIDS (IeDEA).

P2860

Q24605774-33ABB407-CE34-4607-98BE-0DFA983AD643 Q26768632-B9C129BC-C8DD-4084-AA12-47BE7210F491 Q33629439-F4B7146B-BC4F-4339-83EB-A5E065A0FB0D Q34153838-4D28DDC0-8DEB-4DA6-A456-6AA812026AE4 Q34472398-084E86DE-DC2C-402A-BF88-7A3FCDAFAB2C Q34481365-312AA49F-242E-4397-8A32-9AB78D0F488A Q34517582-E799A769-B002-4413-9842-892F3306EA77 Q34638302-200D4014-6E0D-495F-AAF6-96861142FEC6 Q34737260-3D4A31FE-D0D1-44F7-A89C-24EEFA91FB04 Q34754376-9875BABC-2F2E-4A43-9601-92E297347CD5 Q34870233-9E96A36C-6996-4E41-887C-21FBC62F7100 Q34904319-5CACE848-5983-40DF-ACF0-48A87FAC45EA Q35088773-C429385C-58B1-4657-B7FA-188086216C37 Q35093189-D356ADD5-5100-47CC-B766-43CFCE5F9CF4 Q35127445-24F1FF6A-E1F0-47B6-905B-96CBE9276DCF Q35195625-CE836132-88E4-4D50-A9AE-A18D7D682432 Q35546757-0E330A11-3C66-4611-9EDA-89D77535161C Q35867025-11685643-3E5B-452A-91C5-B44A9D5BCEB4 Q35896106-C6F78BDA-37C5-4768-8BA1-D50712DDBC1A Q35908984-C5D1644F-1005-45DF-8081-76BCF3E69970 Q35944787-F1366308-A1A9-41DE-B383-D9B921C282C5 Q35953569-FD9C6EE7-4761-4C34-B6A7-4CBD881765C0 Q36157703-7DF2E63A-B151-46C9-8631-B2780918393B Q37212049-E7AB005B-7FF0-414C-8A0C-DAA58CD20135 Q37259757-1C9F8312-0CBA-46FD-813B-DA8E44323DDD Q37410986-D0B4C720-614D-4178-8CE5-AE7D042F28D5 Q37417396-BB9C206C-1E89-4437-A06A-0AAE462DC857 Q38058385-FB85BE14-CD12-44DC-B7C5-7953692129A0 Q38069146-8AB1F7E5-B4EF-4941-ABFC-344573D01BE0 Q38171346-BD31ED2D-82AC-4053-B6D3-E3FBE9898F0C Q38440869-84C93053-D67B-40BE-B169-1270C1226E6B Q38853255-601A7998-1869-4C14-A79C-9FBEA48347BA Q39372748-77B9F0C0-7213-4AA8-B34B-D80C8B4A1A27 Q40048002-9D7EDA80-3B94-49D4-927B-6F6E5AE3C82F Q40860723-28CB6AD9-D3A5-4A71-9964-D0E7691347EE Q42205021-39CF11F5-4CA3-44C3-90CE-07D94B3CA1C7 Q45746984-20F00249-3B90-4787-A5B8-90D75AB80336 Q50512959-79576365-829B-4AF3-B034-EF25E1735C3C Q52674721-BF27A4CE-6669-4862-A6EE-D6E50C80F26F Q55425622-8ED038D8-C599-4044-BE1D-6B8D3898D91D

P2860

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

http://www.wikidata.org/entity/Q34664004

description

2010 nî lūn-bûn

@nan

2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

@ast

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

@en

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

@nl

type

label

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

@ast

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

@en

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

@nl

prefLabel

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

@ast

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

@en

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

@nl

P1433

Q34664004-452DBC5A-7289-4149-9A8C-F6FAEB02D325

P1476

Q34664004-D8080534-59C9-4D62-8649-4462C6DA2FDB

P2093

Q34664004-01618944-C220-45A1-95A9-4560D5C902E7

Q34664004-0E8F9EF2-C6FA-4C18-8D06-94A087A65F73

Q34664004-4118F879-B2E2-4A4E-845F-5EFBF482C872

Q34664004-540CF578-CBA4-4E0C-BD56-229B14E53BFC

Q34664004-7383814A-216A-4AE2-8FFF-624749AC7BB9

Q34664004-A24C53BD-1DD1-45D7-BC6E-E47533CBFC95

Q34664004-A360FA35-73F3-4B31-94E7-E9C6F81F6E11

Q34664004-CFC34BCB-17A9-4BA1-8201-AE79CC89E8F5

Q34664004-E04E67D0-754D-44F2-A631-5C1672593EBA

Q34664004-ED5CED3B-35DE-4CBC-BE21-438F775F2FF9

P2860

Q34664004-05123FB2-99CC-4F56-A7A3-F673DE4851F4

Q34664004-090BE694-E3AC-49AA-A07E-D03621810EB8

Q34664004-14EB7829-CBA7-4333-99C8-F5ECC3C82F57

Q34664004-1704CD16-AA8E-4E9C-B1B5-3AB64EFF9A1A

Q34664004-1D51FF27-23AA-4382-9D20-9591767A9A6C

Q34664004-31AA590D-5D2D-4F68-B603-EB82D46A854A

Q34664004-506A448B-0AA0-4F5B-A4DC-FC541AEBD753

Q34664004-5D4F5366-0B96-4D4A-8DA3-D9DD25C43E6C

Q34664004-673117C4-EA59-4F36-8DE9-C09928D64A94

Q34664004-724BD63D-0C82-4B64-85EB-46F93A573305

P304

Q34664004-09F04726-E704-4B0B-BB56-0A751D6F21F7

P31

Q34664004-43C0AC4A-0204-46F4-BA8C-3867C47B0461

P356

Q34664004-8DFD23C4-2BA7-402E-B367-D573B914676C

P407

Q34664004-12B02E66-ECA3-42DB-B0C2-4D7FF4078B49

P433

Q34664004-33A7CC53-721D-4013-837C-462CFD57E05F

P478

Q34664004-D236C831-64B3-409C-9779-49643CCB15D7

P577

Q34664004-E95E4D35-0BA4-4BD8-AAE5-B95E0C07E621

P698

Q34664004-5BB6D178-76A5-4C3E-A8A8-ED75CEEB309C

P932

Q34664004-7ED50731-13CC-4888-863B-6A3A04AA1841

P356

0003-4819-153-6-201009210-00002

P1433

Annals of Internal Medicine

P1476

Sex-based outcomes of darunavir-ritonavir therapy: a single-group trial.

@en

P2093

Alan Tennenberg

http://www.w3.org/2001/XMLSchema#string

Carmen D Zorrilla

http://www.w3.org/2001/XMLSchema#string

Dawn Averitt Bridge

http://www.w3.org/2001/XMLSchema#string

Debbie Hagins

http://www.w3.org/2001/XMLSchema#string

GRACE (Gender, Race, And Clinical Experience) Study Group

http://www.w3.org/2001/XMLSchema#string

Joseph Mrus

http://www.w3.org/2001/XMLSchema#string

Judith Currier

http://www.w3.org/2001/XMLSchema#string

Judith Feinberg

http://www.w3.org/2001/XMLSchema#string

Kathleen Squires

http://www.w3.org/2001/XMLSchema#string

Robert Ryan

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.

Gender bias in clinical trials: do double standards still apply?

Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.

Sex differences in antiretroviral therapy-associated intolerance and adverse events.

Sex differences in pharmacokinetics and toxicity of antiretroviral therapy.

Sex issues in HIV-1-infected persons during highly active antiretroviral therapy: a systematic review.

Gender differences in predictors of treatment attrition with high dose naltrexone in cocaine and alcohol dependence

Attrition from randomized controlled trials of pharmacological weight loss agents: a systematic review and analysis.

Gender differences in discontinuation of antiretroviral treatment regimens.

Representation of women in randomized clinical trials of cardiovascular disease prevention.

P304

349-357

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.7326/0003-4819-153-6-201009210-00002

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

153

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20855799

http://www.w3.org/2001/XMLSchema#string

P932

3056066

http://www.w3.org/2001/XMLSchema#string